SEHK:8329

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Shenzhen Neptunus Interlong Bio-technique

Executive Summary

Shenzhen Neptunus Interlong Bio-technique Company Limited researches, develops, produces, and sells medicines in the People’s Republic of China. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has Shenzhen Neptunus Interlong Bio-technique's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8329 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 8329's weekly volatility has decreased from 22% to 7% over the past year.


Market Performance


7 Day Return

-1.5%

8329

-0.8%

HK Pharmaceuticals

1.1%

HK Market


1 Year Return

34.0%

8329

3.1%

HK Pharmaceuticals

8.2%

HK Market

Return vs Industry: 8329 exceeded the Hong Kong Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 8329 exceeded the Hong Kong Market which returned 7.6% over the past year.


Shareholder returns

8329IndustryMarket
7 Day-1.5%-0.8%1.1%
30 Day-5.6%-2.1%7.2%
90 Day-8.2%-11.2%5.2%
1 Year34.0%34.0%4.8%3.1%12.6%8.2%
3 Year-18.3%-18.3%-4.5%-10.0%0.4%-10.0%
5 Year-52.1%-52.1%28.9%18.7%30.6%8.5%

Long-Term Price Volatility Vs. Market

How volatile is Shenzhen Neptunus Interlong Bio-technique's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Shenzhen Neptunus Interlong Bio-technique undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 8329 (HK$0.34) is trading below our estimate of fair value (HK$2.05)

Significantly Below Fair Value: 8329 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 8329 is good value based on its PE Ratio (9.2x) compared to the HK Pharmaceuticals industry average (10.7x).

PE vs Market: 8329 is good value based on its PE Ratio (9.2x) compared to the Hong Kong market (11.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8329's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8329 is good value based on its PB Ratio (0.6x) compared to the HK Pharmaceuticals industry average (1.1x).


Next Steps

Future Growth

How is Shenzhen Neptunus Interlong Bio-technique forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shenzhen Neptunus Interlong Bio-technique has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Shenzhen Neptunus Interlong Bio-technique performed over the past 5 years?

11.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8329 has a large one-off loss of CN¥24.3M impacting its September 30 2020 financial results.

Growing Profit Margin: 8329's current net profit margins (4.8%) are lower than last year (5.6%).


Past Earnings Growth Analysis

Earnings Trend: 8329's earnings have grown by 11.8% per year over the past 5 years.

Accelerating Growth: 8329's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 8329 had negative earnings growth (-7.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-11.9%).


Return on Equity

High ROE: 8329's Return on Equity (6.1%) is considered low.


Next Steps

Financial Health

How is Shenzhen Neptunus Interlong Bio-technique's financial position?


Financial Position Analysis

Short Term Liabilities: 8329's short term assets (CN¥777.3M) exceed its short term liabilities (CN¥195.1M).

Long Term Liabilities: 8329's short term assets (CN¥777.3M) exceed its long term liabilities (CN¥13.4M).


Debt to Equity History and Analysis

Debt Level: 8329's debt to equity ratio (4%) is considered satisfactory.

Reducing Debt: 8329's debt to equity ratio has reduced from 28.6% to 4% over the past 5 years.

Debt Coverage: 8329's debt is well covered by operating cash flow (445.4%).

Interest Coverage: 8329 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Shenzhen Neptunus Interlong Bio-technique current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8329's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8329's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8329's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8329's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8329's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Hang Zhou (49 yo)

0.42

Tenure

Mr. Hang Zhou has been General Manager, Authorized Representative & Executive Director of Shenzhen Neptunus Interlong Bio-technique Company Limited since June 25, 2020. Mr. Zhou has more than years of expe...


Leadership Team

NamePositionTenureCompensationOwnership
Feng Zhang
Executive Chairman & Compliance Officer9.42yrsCN¥100.00kno data
Hang Zhou
GM, Authorized Representative & Executive Director0.42yrno datano data
Jian Bo Huang
Vice GM & Executive Director0.42yrno datano data
Zong Lei
Chief Engineer of the Production Project17.25yrsno datano data
Wai Sum Fung
Joint Company Secretary0.42yrno datano data
Tao Sun
Sales Controller13.83yrsno datano data

5.0yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 8329's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Feng Zhang
Executive Chairman & Compliance Officer9.42yrsCN¥100.00kno data
Hang Zhou
GM, Authorized Representative & Executive Director0.42yrno datano data
Jian Bo Huang
Vice GM & Executive Director0.42yrno datano data
Wing Fat Yick
Independent Non-Executive Director15.25yrsCN¥212.00kno data
Lin Be Yu
Non-Executive Director15.75yrsCN¥100.00kno data
Da Kai Shen
Non-Executive Director0.42yrno datano data
Ka Yeung Poon
Independent Non-Executive Director15.25yrsCN¥106.00kno data
Chu Xiong Xiong
Chairman of the Supervisory Committee0.42yrno datano data
Yan He Xu
Non-Executive Director9.42yrsCN¥695.00kno data
Bin Wang
Supervisor9.42yrsno datano data
Jian Zhou Zhang
Independent Non-Executive Director4.83yrsCN¥100.00kno data
Yang Cao
Employee Representative Supervisor2.5yrsno datano data

7.1yrs

Average Tenure

54.5yo

Average Age

Experienced Board: 8329's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shenzhen Neptunus Interlong Bio-technique Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shenzhen Neptunus Interlong Bio-technique Company Limited
  • Ticker: 8329
  • Exchange: SEHK
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$570.520m
  • Shares outstanding: 1.68b
  • Website: https://www.interlong.com

Number of Employees


Location

  • Shenzhen Neptunus Interlong Bio-technique Company Limited
  • Neptunus Yinhe Technology Mansion
  • Suite 2103, 21st Floor
  • Shenzhen
  • Guangdong Province
  • 518000
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
8329SEHK (The Stock Exchange of Hong Kong Ltd.)YesForeign Shares-Foreign ListedHKHKDSep 2005

Biography

Shenzhen Neptunus Interlong Bio-technique Company Limited researches, develops, produces, and sells medicines in the People’s Republic of China. The company is also involved in the purchase and sale of med...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 10:13
End of Day Share Price2020/11/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.